AtheroGenics Converts Ch. 7 Bankruptcy Into Ch. 11
AtheroGenics, which develops drugs to treat chronic inflammatory diseases such as diabetes and coronary heart disease, said in a statement that during the bankruptcy proceeding, it plans to sell off either the entire company or its key assets.
Proceeds from the transactions will be used to pay creditors...
To view the full article, register now.